Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119408 | 0.80 | ACACB (0.40) | KCNH2TMEM97SIGMAR1HTR2BACACB | |
| SCHEMBL26136927 | 0.80 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL20178629 | 0.78 | NOTUM (0.32) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL20173787 | 0.71 | HTR2A (0.44) | KCNH2TMEM97SIGMAR1HTR2AHTR2C | |
| SCHEMBL20173791 | 0.71 | MITF (0.32) | — | |
| SCHEMBL21882589 | 0.70 | ACACB (0.38) | KCNH2TMEM97SIGMAR1ACACB | |
| SCHEMBL13243094 | 0.69 | KCNH2 (0.58) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL21882590 | 0.69 | — | — | |
| SCHEMBL13938028 | 0.68 | TMEM97 (0.54) | KCNH2TMEM97SIGMAR1HTR2BACACB | |
| SCHEMBL21882595 | 0.68 | KCNH2 (0.44) | KCNH2TMEM97SIGMAR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | PDE2A 781/4885KCNH2 4447/4885TMEM97 192/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | PDE2A 781/4885KCNH2 4447/4885TMEM97 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.